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Objective: We sought to determine the effects of oxidative stress
on mitochondrial function in the pathophysiology of airway
inflammation in ozone-exposed mice and human airway smooth
muscle (ASM) cells.
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http://dx.doi.org/10.1016/j.jaci.2015.01.046Results: Mice exposed to ozone, a source of oxidative stress, had
lung inflammation and AHR associated with mitochondrial
dysfunction and reflected by decreased mitochondrial
membrane potential (DCm), increased mitochondrial oxidative
stress, and reduced mitochondrial complex I, III, and V
expression. Reversal of mitochondrial dysfunction by the
mitochondria-targeted antioxidant MitoQ reduced
inflammation and AHR. ASM cells from patients with COPD
have reduced DCm, adenosine triphosphate content, complex
expression, basal and maximum respiration levels, and
respiratory reserve capacity compared with those from healthy
control subjects, whereas mitochondrial reactive oxygen species
(ROS) levels were increased. Healthy smokers were
intermediate between healthy nonsmokers and patients with
COPD. Hydrogen peroxide induced mitochondrial dysfunction
in ASM cells from healthy subjects. MitoQ and Tiron inhibited
TGF-b–induced ASM cell proliferation and CXCL8 release.
Conclusions: Mitochondrial dysfunction in patients with COPD
is associated with excessive mitochondrial ROS levels, which
contribute to enhanced inflammation and cell
hyperproliferation. Targeting mitochondrial ROS represents a
promising therapeutic approach in patients with COPD. (J
Allergy Clin Immunol 2015;136:769-80.)
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Chronic obstructive pulmonary disease (COPD) is the third
most common cause of death worldwide, mainly as a result of
cigarette smoking in the developed world.1 COPD is character-
ized by chronic inflammation and development of airflow
limitation caused by airway remodeling and destruction of lung
tissue.1 Tobacco smoke induces local inflammation and enhances
oxidative stress in the lung, affecting the oxidant-antioxidant
balance, which is thought to be one of the major driving
mechanisms in the development of COPD.2 Production of
reactive oxygen species (ROS) in the mitochondria occurs as a
byproduct of oxidative phosphorylation at the mitochondrial
electron transport chain.3 Normally, ROS are cleared by the
actions of antioxidants, such as glutathione, vitamins C and E,
and enzymes, including catalases, peroxidases, and superoxide
dismutases.4 Increased ROS levels or a reduction in antioxidant
capacity can influence redox-sensitive cellular processes,
including mitochondrial apoptosis.5769
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triphosphate (ATP), although they are also involved in other
cellular functions, including redox homeostasis, ROS and
nicotinamide adenine dinucleotide phosphate generation,
calciummetabolism, and apoptosis.6Mitochondria can also sense
danger signals and induce inflammation by activating and
controlling the innate immune system.7 Indeed, alterations in
cellular metabolism have a profound effect on immunology and
cell biology, particularly in patients with cancer in whom
mitochondrial function is directly regulated by oncogenes and
tumor suppressors and might be involved in oncogenic
transformation.8
Genetic defects in mitochondrial function are associated with
diseases, such as Leigh disease and mitochondrial encephalomy-
opathy, lactic acidosis, and stroke-like syndrome.9 These diseases
are associated with mitochondrial DNA mutations, which cause
defects in respiratory chain function and energy production. Path-
ogenic mitochondrial DNA mutations are rare (1:10,000) and
largely affect children.9 In addition, mitochondrial defects have
been linked to diseases of aging resulting from exposure to oxida-
tive stress.10
Airway wall remodeling in patients with COPD involves tissue
repair and epithelial metaplasia, increased mucous metaplasia
and submucosal gland hypertrophy, peribronchial fibrosis, and an
increase in airway smooth muscle (ASM) mass.11 In addition to
their contractile properties, ASM cells produce inflammatory
mediators thought to drive, at least in part, the airway wall
remodeling seen in patients with COPD.11 ASM cells from
patients with COPD have a distinct phenotype compared with
that of cells from healthy subjects.12 Specific therapies targeting
ASM cells might be essential in treating airway remodeling in
these patients.
Ozone is an oxidizing environmental pollutant associated with
worsening of symptoms in patients with asthma and COPD13 and
increased morbidity and mortality rates in patients with cardio-
vascular and respiratory disorders.14,15 Ozone exposure in mice
induces airway inflammation, airway hyperresponsiveness
(AHR),16 and lung destruction similar to that observed in patients
with COPD.17 Ozone has been hypothesized to initiate intracel-
lular oxidative stress through formation of ozonide and hydrogenperoxide.18 In turn, these are able to produce ROS that can alter
gene transcription through redox-mediated signaling pathways.19
We previously reported that acute and chronic exposure to ozone
results in persistent inflammation and AHR, which are in part
reversible by treatment with the antioxidant N-acetylcysteine
(NAC).20,21
Here we show a marked alteration in mitochondrial function
associated with increased inflammation and alterations in AHR in
an ozone-induced animal model of COPD. In addition, there is
abnormal mitochondrial function in ASM cells from patients with
COPD, and this is induced by oxidative stress in ASM cells from
healthy subjects. Antioxidants that are targeted to decrease
mitochondrial oxidative damage specifically led to reduced
inflammation and ASM proliferation.METHODS
A more detailed description of the Methods can be found in this article’s
Online Repository at www.jacionline.org.Subjects
This study was approved by the Ethics Committee of the Royal Brompton
& Harefield Hospitals National Health Service Trust. All subjects provided
written informed consent. Healthy nonsmokers (n 5 15), healthy smokers
(n5 10), and patients with COPD (n5 14) were recruited (Table I). In a sepa-
rate study endobronchial biopsy specimens were obtained from 4 exsmokers
with COPD and 4 healthy exsmokers matched for smoking history, age, and
sex (Table II).Fiberoptic bronchoscopy and culture of ASM cells
Spirometry was performed and lung function was recorded before
bronchoscopy, as previously described.22 All subjects had bronchial biopsy
specimens taken. ASM cells were isolated from bronchial biopsy specimens,
as previously described.23 ASM cells were cultured in supplemented
Dulbecco modified Eagle medium and used at passages 3 and 6. ASM cells
were incubated in supplemented serum-free medium for 18 hours before
experiments23 and used to measure various parameters of mitochondrial
function. In other subjects intact mitochondria were isolated from fresh
bronchial biopsy specimens, and membrane potential and mitochondrial
ROS levels were measured.Mouse AHR and bronchoalveolar lavage
Experiments were performed under a Project License from the British
HomeOffice, United Kingdom, under the Animals (Scientific Procedures) Act
1986. Male C57BL/6 mice (6 weeks old; Harlan, Wyton, United Kingdom)
were exposed to ozone (model 500 Ozoniser; Sander, Wuppertal, Germany)
mixed with air (3-ppm concentration), as previously described.20,21 Lung
function and AHR were measured and bronchoalveolar lavage (BAL) fluid
and tissue collection was performed 24 hours after the last exposure.20,21
Resistance/compliance measures were obtained from tracheostomized and
ventilated mice by using whole-body plethysmography (EMMS, Hants,
United Kingdom), as previously described.20 Lung resistance (RL) was ex-
pressed as the percentage change from baseline RL with nebulized PBS
(Sigma, St Louis,Mo). The concentration of acetylcholine required to increase
RL by 100% from baseline was calculated (PC100), and the concentration of
acetylcholine that increased lung resistance by 100% (2logPC100) was taken
as a measure of AHR.20,21 BAL samples and cytospin preparations were
obtained and analyzed, as previously described.20,21 Keratinocyte-derived
cytokine (KC), IL-6, and GM-CSF levels in BAL fluid were measured with
commercial ELISA kits (R&D Systems Europe Ltd, Abingdon, United
Kingdom).
TABLE I. Demographics of subjects undergoing bronchoscopy
from whom ASM cells were obtained
Healthy
subjects Smokers
Patients
with COPD
No. 15 10 14
Age (y) 41.20 6 3.74 57.10 6 1.85* 68.2 6 1.85k
Sex (male/female) 9/6 7/3 7/7
Pack years smoking NA 34.67 6 3.64 50.95 6 4.68§
FEV1 (L) 4.10 6 0.21 2.85 6 0.23 1.69 6 0.12§
FEV1 (% predicted) 106.70 6 3.1 92.75 6 5.76 61.66 6 3.72{
FVC (L) 5.16 6 0.39 3.96 6 0.33 3.23 6 0.22
FVC (% predicted) 111.2 6 4.31 105.7 6 5.73 101.4 6 5.22
FEV1/FVC ratio (%) 88.33 6 3.04 75.40 6 3.33 52.57 6 3.02{
FVC, Forced vital capacity; NA, not applicable.
*P < .05 versus healthy subjects.
P < .01 versus healthy subjects.
P < .001 versus healthy subjects.
§P < .05 versus smokers.
kP < .01 versus smokers.
{P < .001 versus smokers.
TABLE II. Demographics of subjects undergoing bronchos-
copy from whom mitochondria were freshly isolated
Healthy subjects Patients with COPD
No. 4 4
Smoking (pack years) 34 6 6 36 6 8
FEV1 (% predicted) 99 6 6 72 6 2*
*P < .01 versus healthy subjects.
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specimens and murine lung tissue
Intact mitochondria were isolated with a Mitochondria Isolated Kit for
Tissue (Thermo Scientific, Waltham, Mass), exactly as described by the
manufacturer.RNA isolation and microarrays
RNA isolation and microarrays were performed exactly as previously
described.24,25 Quantitation and quality assessment of the RNA preparations
were performed by using Nanodrop analysis (Nanodrop Technologies,
Wilmington, Del) and the Agilent 2100 bioanalyzer and the RNA 6000
LabChip kit (Agilent Technologies, Palo Alto, Calif), respectively. cDNA
was run on Mouse Genome 430 array (HT plate format) Affymetrix chips,
and gene expression profiles were examined with Ingenuity pathway anal-
ysis (Ingenuity Systems, Redwood City, Calif) and Partek Genomics suit
6.6 beta software. Expression of selected genes was confirmed by means
of TaqMan (Applied Biosystems, Foster City, Calif) quantitative PCR
analysis.Mitochondrial respiration
Mitochondrial respiration was determined by measuring oxygen
consumption rates (OCRs) in the extracellular space with a Seahorse XF24
Extracellular Flux Analyzer and the XF Cell Mito Stress Test kit (Seahorse
Bioscience, North Billerica, Mass), according to the manufacturer’s
instructions. ASM cells (105 cells per well) were seeded in a 24-well plate
and serum starved overnight.ATP determination and complex I activity
ATP levels were quantified with a bioluminescence ATP determination
assay (Molecular probes, Eugene, Ore). Complex I enzyme activity levels
were determined based on oxidation of NADH to NAD1 with a commercial
assay (MitoSciences, Eugene, Ore).Mitochondrial membrane potential
Mitochondrial membrane potential (DCm) was measured in human ASM
cells and isolated mitochondria (human biopsy and mouse lung) by using the
cationic dye 5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolylcarbo-
cyanine iodide (JC-1; Invitrogen, Carlsbad, Calif). ASM cells and isolated
intact mitochondria were incubated with 3 mmol/L JC-1 for 30 minutes at
378C and 5% CO2. JC-1 monomers emit green fluorescence, but when theyenter live mitochondria, they form J-aggregates, which emit red fluorescence.
An increase in the ratio between red and green fluorescence is an indicator
of DCm.Mitochondrial ROS analysis
Mitochondrial ROS activity was measured with MitoSOX Red
(Invitrogen), a redox-sensitive fluorescent probe that is selectively targeted
to the mitochondria. ASM cells and intact isolated mitochondria were
incubated with 5 mmol/L MitoSOX for 30 minutes at 378C and 5% CO2,
and red fluorescence was determined at 510/580 nm by using a fluorescence
plate reader or by means of flow cytometry.Immunoblotting
Cell, tissue, and mitochondrial protein fractions were separated on 10%
NuPAGE gels, and proteins were detected, as previously described.21 The
following antibodies were used: MitoProfile Total OXPHOS Rodent WB
Antibody Cocktail and MitoProfile Total OXPHOS Human WB Antibody
Cocktail (MitoSciences).Statistical analysis
Data from in vivo experiments are expressed as means 6 SDs. The
Kruskal-Wallis test for ANOVAwas used for multiple comparisons of different
groups. The Mann-Whitney test was subsequently used when results on the
Kruskal-Wallis test were significant. Power calculations determined that 6 an-
imals per group have 80% power to detect significant difference in lung param-
eters. Data from in vitro experiments are expressed asmeans6 SEMs and were
analyzed by using 1-way ANOVA for repeatedmeasures, followed by the Dun-
nett or Bonferroni post hoc test. The Mann-Whitney test was used for compar-
isons between disease groups. Statistical analysis was performed with
GraphPad Prism 4 software (GraphPad Software, San Diego, Calif). A P value
of less than .05 was accepted as statistically significant.RESULTS
Ozone-induced AHR and lung inflammation in mice
AHR to acetylcholine was measured in air- and ozone-exposed
mice. Therewere greater increases in RL inmice exposed to ozone
for both 1 and 6 weeks compared with that seen in air-exposed
animals (Fig 1, A). AHR was observed in both 1- and
6-week-exposed mice. The 2logPC100 value was decreased in
1-week-exposed (1.5-fold) and 6-week-exposed mice (1.6-fold;
Fig 1, B).
Ozone-exposed mice showed marked increases in total BAL
cell counts compared with those in air-exposed control mice after
1 and 6 weeks, with increased neutrophil, lymphocyte, macro-
phage, and eosinophil counts (Fig 1, C-G). One and 6 weeks of
ozone exposure also induced an increase in proinflammatory
cytokine profiles in BAL fluid, including GM-CSF, KC, and
IL-6 (Fig 1, H-J). Gene microarray analysis of lung samples
from these ozone-exposed mice demonstrated significantly
increased (>2-fold) expression of 116 genes (see Table E1 in
this article’s Online Repository at www.jacionline.org) and
FIG 1. A and B, Airways hyperresponsiveness measured as RL (Fig 1, A) and 2logPC100 (Fig 1, B). C-J, BAL
fluid total cell (Fig 1, C), neutrophil (Fig 1, D), lymphocyte (Fig 1, E), macrophage (Fig 1, F), and eosinophil
(Fig 1, G) counts and GM-CSF (Fig 1, H), KC (Fig 1, I), and IL-6 (Fig 1, J) levels were measured. Data are
expressed as means 6 SDs of 6-8 mice per group. *P < .05, **P < .01, and ***P < .001 compared with
air-exposed control group. #P < .05 compared with 1-week ozone-exposed group.
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TABLE III. Gene ontology analysis of ozone-treated lungs:
Identification of processes
P value Benjamini FDR
Processes upregulated
Cyclin/proliferation 5.4E-06 9.8E-04 1.0E-03
Inflammation 1.7E-02 1.0E-03 2.6E-02
Lipid biosynthesis 1.1E-04 2.0E-03 4.7E-02
Processes downregulated
Mitochondria function 1.3E-07 1.9E-06 8.7E-05
FDR, False discovery rate.
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ticle’s Online Repository at www.jacionline.org). Gene ontology
analysis provided evidence for increased inflammation and cell
proliferation at the mRNA level at 6 weeks (Table III). These
effects of ozone on inflammation aremodulated through oxidative
stress.20 Gene ontology analysis of the ozone-modulated genes
also indicated a significant effect on genes associated with
mitochondrial function (Table III).
The top differentially upregulated and downregulated genes in
the 6-week ozone model were defined as an ozone gene
expression ‘‘signature’’ and compared with the transcriptomic
GEO data set (GSE20257) containing gene array data from
epithelial cells from smokers and patients with COPD (Global
Initiative for Chronic Obstructive Lung Disease [GOLD] stage
1-3). Gene Set Variation Analysis showed increased association
of the mouse ozone ‘‘signature’’ with COPD severity (P <.05, see
Fig E1 in this article’s Online Repository at www.jacionline.org).Mitochondrial function is impaired in lungs of
ozone-exposed mice
We examined whether mitochondrial function was altered in
the lungs of ozone-exposed mice. Mitochondria were isolated
from lung tissue and incubated with the fluorescent probes JC-1 or
MitoSOX. DCm was decreased in 1-week (2.0-fold) and 6-week
(2.4-fold) ozone-exposed mice (Fig 2, A). Mitochondrial
ROS levels were increased in the lungs of 1- and 6-week
ozone-exposed mice (1.9- and 2.1-fold, respectively; Fig 2, B).
ATP content was decreased 2.5- and 1.7-fold in intact
mitochondria isolated from 1- and 6-week ozone-exposed mice,
respectively (see Fig E2, A, in this article’s Online Repository
at www.jacionline.org). Complex I enzyme activity levels
measured based on NADH consumption rates in isolated
mitochondria were decreased 1.4- and 4.6-fold in 1- and
6-week ozone-exposed mice, respectively (see Fig E2, B).
Protein expression levels measured by using Western blot
analysis (see Fig E2, C) were reduced for complex I (NADH
dehydrogenase), complex III (cytochrome bc1 complex), and
complex V (FoF1-ATPase; see Fig E2, D-F) in 1- and 6-week
ozone-exposed groups compared with those in air-exposed con-
trol ice. Complex III and V levels were more profoundly
decreased in 6-week-exposed compared with 1-week-exposed
mice, whereas complex I reduction was similar for both
ozone-exposed groups.MitoQ reverses ozone-induced AHR and
inflammation
MitoQ is a combination of ubiquinone, an endogenous
antioxidant and component of the mitochondrial electrontransport chain, and a decyltriphenylphosphonium bromide
(dTPP) cation, the latter allowing it to concentrate in mitochon-
dria.26 Treatment of mice with MitoQ (5 mg/kg administered
intraperitoneally) resulted in a significant reversal of ozone-
induced AHR compared with treatment with the control cation,
dTPP, as measured based on 2logPC100 values (Fig 2, C and
D). MitoQ treatment also resulted in a reduction in ozone-
induced total BAL cell counts (Fig 2, E) and BAL KC levels
(Fig 2, F) compared with dTPP treatment alone. This was
associated with a restoration of DCm (Fig 2, G), a reduction in
ROS levels in isolated mitochondria (Fig 2, H), and a reduction
in total cellular ROS levels (see Fig E2, G).ASM cells from patients with COPD demonstrate
mitochondrial dysfunction
We studied ASM cells cultured from bronchial biopsy
specimens obtained from patients with COPD of GOLD stage 1
or 2 and ASM cells from healthy nonsmokers and healthy
smokers for comparison (see Table I for the characteristics of
these subjects). Basal GM-CSF (2.5-fold), CXCL8 (1.6-fold),
and IL-6 (1.8-fold) secretions from ASM cells isolated from
smokers and patients with COPD and studied at passage 4 were
increased compared with those from healthy control subjects
(Fig 3, A-C). IL-6 secretion was increased (2.1-fold) in ASM cells
from smokers compared with those from healthy control subjects
(Fig 3, C). Exposure to H2O2 (100 mmol/L for 4 hours) increased
GM-CSF, CXCL8, and IL-6 secretion from ASM cells in all
subject groups (Fig 3, A-C).
DCm (Fig 3, D) was lower in unstimulated ASM cells from
smokers (2.0-fold) and patients with COPD (2.3-fold) compared
with those from healthy control subjects. H2O2 exposure led to a
reduction in DCm and an increase in mitochondrial ROS levels,
which were reversed by prior exposure to NAC (Fig 3, E and
F). However, H2O2 did not significantly decrease DCm in ASM
cells from smokers and patients with COPD (Fig 3, G). H2O2
increased mitochondrial ROS levels in all groups, with the
greatest stimulation in ASM cells isolated from patients
with COPD (Fig 3, H). Basal mitochondrial ROS levels, as
determined by the mean fluorescence intensity, differed
between healthy nonsmokers (median, 236.0; 95% CI,
154.3-331; n 5 9), healthy smokers (median, 587.9; 95% CI,
130.9-1045; n 5 8), and patients with COPD (median, 337.0;
95% CI, 228.2-804.7; n 5 16), although this did not reach
significance (P5 .06, ANOVA). Within each patient group, there
was no age-related difference in mitochondrial ROS and DCm
values.
To determine whether the changes in mitochondrial ROS and
membrane potential observed in ASM cells reflect changes in the
lung at the organ level, we isolated intact mitochondria from
bronchial biopsy specimens from control subjects and patients
with COPD. DCm was lower in lungs from patients with COPD
compared with those from healthy control subjects (Fig 3, I).
Mitochondrial ROS levels were increased in patients with
COPD compared with those in healthy control subjects (Fig 3,
J). These results are similar to those observed in ASM cells and
confirm the ASM cell phenotype.
In view of the differences in mitochondrial ROS andmembrane
potential observed in endobronchial biopsy specimens and ASM
cells from patients with COPD compared with cells from healthy
nonsmokers, we next made real-time measurements of the OCR
FIG 2. A, B, G, and H,Membrane potential (DCm; Fig 2,A andG) andmitochondrial ROS (Fig 2, B andH) after
ozoneexposure.C,D,E,andF,RL (Fig2,C),2logPC100 (Fig 2,D), BAL total cell counts (Fig2,E), andKC levels (Fig
2, F) were determined. DCm (Fig 2, G) and ROS content (Fig 2, H) were determined in isolated mitochondria.
Data are expressed as means 6 SDs of 5-8 mice per group. *P < .05, **P < .01, and ***P < .001 compared
with air-exposed control group. #P < .05 and ##P < .01 compared with ozone-exposed group.
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FIG 3. ASM cells from healthy subjects, smokers, and patients with COPD were treated with H2O2 with and
withoutNACbefore treatment.A-C,GM-CSF (Fig3,A), CXCL8 (Fig 3,B), and IL-6 (Fig3,C) levelsweredetermined
by means of ELISA. D-H, DCm (Fig 3, D, E and G) and mitochondrial ROS values (Fig 3, F and H) were also
measured.Bars representmeans6 SEMs of 5 to 6 donors per group. *P < .05 and **P < .01. I-J, Intactmitochon-
driawere isolatedfrombronchialbiopsiesfromhealthysubjectsandCOPDpatients.DCm(Fig3, I)andmitochon-
drial ROS values (Fig 3, J) were measured. Dot plots represent means6 SD of 4 subjects or patients per group.
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in this article’s Online Repository at www.jacionline.org).
A significant reduction in basal OCR was measured in ASM
cells isolated from patients with COPD (P <.05; Fig 4, E, and see
Fig E3, A) compared with ASM cells isolated from healthy
control subjects (Fig 4, A), although there was a trend toward a
reduction in basal OCRs in healthy smokers (P 5 .0512; Fig 4,
C, and see Fig E3, A). In the presence of oligomycin, which
inhibits the activity of ATP synthase, the ATP-linked OCR was
measured. Carbonyl cyanide p-(trifluormethoxy)phenylhydra-
zone, an uncoupler of oxidative oxidation, was added to assess
maximal respiration capability. This was followed by adding
rotenone and antimycin A, which are complex I and III inhibitors,
respectively, to determinemaximal OCR. TheOCR linked to ATP
generation (see Fig E3, B) was reduced in ASM cells from
patients with COPD only. However, the maximal OCR (see
Fig E3, C) was significantly lower in ASM cells from both
smokers and patients with COPD, resulting in a significantly
attenuated reserve capacity in mitochondria from smokers and
cells from patients with COPD (see Fig E3, D).
The membrane potential in unstimulated ASM cells from
healthy smokers and nonsmokers could be fully depolarized with
the uncoupler carbonyl cyanide m-chlorophenyl hydrazone (see
Fig E3, E). This did not occur with cells from patients with
COPD, possibly because these already had a reduced membrane
potential. Inhibition of complex III with antimycin A prevents all
mitochondrial respiration, leading to enhanced mitochondrial
ROS in ASM cells from all subject groups, with the highest
increase in ASM cells from healthy subjects (see Fig E3, F).
Oxidative stress reduces OXPHOS expression in
ASM cells
There was a reduced production of cellular ATP in cells from
healthy smokers and patients with COPD compared with that seen
in healthy nonsmokers (see Fig E4, A, in this article’s Online
Repository at www.jacionline.org), and H2O2 exposure reduced
mitochondrial ATP production in ASM cells from healthy
smokers and nonsmokers but not in patients with COPD. This
was associated with a reduction in expression of mitochondrial
complex proteins (see Fig E4, B-D). Complex I and Vexpression
levels were lower in ASM cells of smokers and patients with
COPD at baseline (see Fig E4, B and D), and complex III levels
were reduced in ASM cells from patients with COPD only (see
Fig E4, C).Inhibition of mitochondrial function attenuates
ASM proliferation and inflammatory responses
TNF-a significantly enhanced CXCL8 release from cells, and
this was significantly reduced by MitoQ compared with the effect
seen with its control, dTPP (Fig 4, H). ASM cells from healthy
subjects (Fig 4, B) demonstrated less proliferation in response
to TGF-b and FBS than cells from smokers (Fig 4,D) and patients
with COPD (Fig 4, F). MitoQ also significantly reduced the
proliferation seen in ASMcells from healthy subjects and patients
with COPD by 50% compared with dTPP. The more potent
mitochondrial ROS scavenger Tiron (Acros Organics, Geel,
Belgium) prevented TGF-b– and FBS-induced ASM prolifera-
tion to a greater extent (Fig 4, G). No treatment used resulted in
significant levels of cell death (data not shown).DISCUSSION
We report decreased DCm, ATP content, and lower complex
protein expression and activity levels in the lungs of mice
chronically exposed to the oxidant gas ozone. In addition, these
ozone-induced processes were reversed by inhibition of
mitochondrial ROS with the mitochondria-targeted antioxidant
MitoQ, which was accompanied by reversal of ozone-induced
lung inflammation and AHR. In addition, we demonstrate a
profound mitochondrial dysfunction of ASM cells obtained from
smokers and patients with COPDwhen compared with ASM cells
from healthy subjects. This is supported by the observations that
DCm, ATP content, respiratory complex protein expression, and
activity levels were all decreased. Thus ASM cells from patients
with COPD are unable to provide adequate respiration and had a
severely reduced respiratory reserve capacity.
Targeting mitochondrial ROS with the mitochondria-targeted
antioxidant MitoQ and the mitochondria-localized antioxidant
Tiron led to a reduction of the increased cytokine secretion and
proliferation of ASMcells from patients with COPD, highlighting
the role for excessive mitochondrial ROS in driving these
abnormalities of the ASM in patients with COPD. In addition,
intact mitochondria isolated from endobronchial biopsy speci-
mens of healthy subjects and patients with COPD showed a
similar difference in phenotype as seen in cultured ASM cells
with increased mitochondrial ROS content and decreased DCm
levels in mitochondria from patients with COPD compared with
healthy control subjects. This also highlights the ability of
isolated ASM cells from patients with COPD to maintain the
COPD phenotype even through several passages in culture. The
intermediate mitochondrial phenotype seen in healthy smokers
compared with patients with COPD and healthy nonsmokers also
indicates that these differences are related to disease rather than
smoke per se. Follow-up of these patients over several years to
determine whether they succumb to COPD will be of interest in
future studies.
The airways in patients with COPD are remodeled with a
thickened epithelium, lamina propria, and adventitia, with ASM
hyperplasia and hypertrophy and deposition of collagen that
might all contribute to the development of AHR.27,28 In the ozone
model AHR is associated with the presence of increased isometric
contractile responsiveness of the airways to acetylcholine,29
which was due to an increased activation of the p38 mitogen-
activated protein kinase. Therefore the AHR we observed here
was likely to be secondary to direct changes in the ASM. Both
ozone-induced AHR and inflammation were reversed by MitoQ,
suggesting that excessive mitochondrial ROS might contribute
directly to these effects. MitoQ has been shown to increase
mitochondrial matrix calcium levels, which could favor Ca21
overload30 and might directly interfere with the contractile
response of ASM. Our data also suggest that targeting mitochon-
drial ROS with mitochondria-directed antioxidants might be
more effective than extracellular antioxidants, such as NAC.20
In a recent study short-term cigarette smoke exposure of mice
resulted in changes in lung energymetabolism, with redirection of
glucose metabolism toward the pentose phosphate pathway,31
which resulted in a lower substrate supply (pyruvate) to the
mitochondria that can directly influence mitochondrial function.
However, there was increased expression of complexes II, III,
and IV and ATPase (complex V) in this model that might
be viewed as a compensatory response to the limited substrate
FIG 4. A-F, Baseline mitochondrial respiration determined by measuring OCR and the effect of MitoQ on
TGF-b 6 FBS–induced DNA synthesis were determined in ASM cells from healthy subjects (Fig 4, A and
B), smokers (Fig 4, C and D), and patients with COPD (Fig 4, E and F). G and H, Effects of Tiron on
TGF-b 6 FBS–induced DNA synthesis (Fig 4, G) and MitoQ on TNF-a–induced CXCL8 release (Fig 4, H)
were determined. Bars represent means 6 SEMs of 3 (Fig 4, A, C, E, G, and H), 8 (Fig 4, B), 6 (Fig 4, D),
and 4 (Fig 4, F) donors. *P < .05, **P < .01, and ***P < .001.
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778 WIEGMAN ET AL(pyruvate) supply to mitochondria. It is likely that the oxidative
drive provided by ozone exposure is much greater than that
with cigarette smoke. Indeed, this is the main reason why the
ozone exposure model is able to induce a COPD-like phenotype
consisting of chronic inflammation, cell infiltration, steroid
resistance, emphysema, and lung remodeling in a matter of weeks
instead of months, which is more common in cigarette smoke
mouse models. In addition, the gene expression signature in the
ozone model associates with human COPD severity. This
association was not present in a short-term cigarette smoke model
when compared with the same human data set (data not shown).
This highlights that although in both models oxidative stress
drives the induced phenotype, ozone exposure seems to induce
a faster and stable COPD phenotype compared with cigarette
smoke exposure.
Little is known currently about the functional state of
mitochondria in patients with COPD. A recent study examined
mitochondrial structure in airway epithelial cells of patients with
advanced COPD (GOLD stage 4). Hoffmann et al32 showed that
bronchial epithelial cells from exsmokers with COPD showed
damaged mitochondrial structure, with depletion of cristae,
increased branching, elongation, and swelling of the mitochon-
dria. This was accompanied by increased manganese superoxide
dismutase and peroxisome proliferator-activated receptor g
coactivator 1a expression and also augmented levels of the
complex VF1a subunit levels. Although the respiratory capacity
of these cells was not measured, the expression of these
mitochondrial proteins would suggest that epithelial cells, despite
expressing damaged mitochondria, might be coping well with
oxidative stress. Mitochondrial dysfunction has also been re-
ported in skeletal and respiratory muscles of patients with
COPD,33,34 although these changes might reflect altered muscle
physiology in sedentary patients rather than reflecting differences
in patients with COPD within the lung.
Abnormalities in mitochondrial function have been described
in ASM cells from asthmatic patients. Increased mitochondrial
mass and enhanced mitochondrial biogenesis were linked to
increased ASM proliferation in asthmatic patients.35 This would
suggest that the mitochondria of ASM cells from asthmatic
patients were able to provide adequate respiration in the context
of mitochondrial respiration at an increased level. ASM cells
from asthmatic patients, particularly those with severe asthma,
have a defective Nrf2–antioxidant response element binding in
addition to a reduced expression of the antioxidant hemoxyge-
nase-1.36 Decreased ATP levels and mitochondrial abnormalities,
including decreased cytochrome c oxidase activity, the loss of
cristae, and mitochondrial swelling, have been described in the
lungs of sensitized mice challenged with ovalbumin.37
Compounds that act as oxidant scavengers, such as esculetin,
vitamin E, and simvastatin, attenuated these features through
reversing mitochondrial dysfunction,38,39 indicating that chronic
mitochondrial ROS might be detrimental to mitochondrial and
airway function in asthma models.
COPD can be considered a disease of the aging lung.40
Mitochondria do more than just supply cellular energy needs to
survive. The cell has evolved to provide numerous resources
andmetabolic mechanisms to support themitochondrial compart-
ment.10 Consequently, mitochondria participate in a myriad of
cellular processes by regulating and sensing various homeostatic
mechanisms that in turn play a vital role in aging and in regulatingthe cell’s response to particular stresses.10 There might be addi-
tional functional consequences of this acquired mitochondrial
dysfunction in cells from patients with COPD, such as alterations
in antiviral signaling41 and susceptibility to cancer.8
We have previously reported increased oxidative and
nitrosative stress in patients with COPD, with the expression of
nitrotyrosine-positive cells inversely correlated with lung
function.42 The enhanced production of oxidative stress by
mitochondria from patients with COPD might contribute to this
increased nitrotyrosine expression because of interactions with
nitric oxide (NO), levels of which are increased in patients with
COPD because of increased expression of NO-synthesizing
enzymes.42 Reactive nitrogen species, formed through the
reaction of NOwith superoxide anions, have potent proinflamma-
tory and oxidizing actions.43 NO also modulates the expression of
cytochrome c oxidase.44 Cytochrome c oxidase (complex IV of
the mitochondrial electron transport chain) is the primary site
of cellular oxygen consumption and is central to oxidative
phosphorylation and ATP generation.44
Under normal physiologic conditions, oxidants serve as ‘‘redox
messengers’’ regulating intracellular signaling, whereas excess
oxidants can induce irreversible damage to cellular components,
leading to apoptosis and/or altered cellular function, including
innate immunity through mitochondria.45
Our observation of mitochondrial dysfunction in patients with
COPD is based on experiments on the ozone-exposed mouse
model and on ASM cells obtained from a restricted group of
patients with COPD. The ozone-exposed mouse model is driven
by oxidative stress, although recapitulating the inflammation and
emphysema aspects of COPD might not mimic all its pathophys-
iologic features, particularly small airway disease in view of its
limited branching anatomy compared with human subjects. ASM
cells were studied at passage 4 or 5 in culture and might not have
kept their original phenotypic abnormalities on successive
passages despite expressing smooth muscle actin and myosin.
However, ASM cells cultured from asthmatic patients show
abnormal levels of mitochondrial fragmentation.46 Finally, we
have restricted ourselves to patients with moderate-to-severe
COPD when this is a complex disease that can manifest in
more diverse phenotypes. Future studies of mitochondrial
dysfunction in patients with COPD should examine fresh tissues
to confirm these abnormalities in diverse phenotypes, including
frequent exacerbators and those with emphysema. In addition,
other cells can be examined, such as bronchial epithelial cells,
in which mitochondrial abnormalities have been recently
reported.32,47
In summary, we have shown mitochondrial dysfunction and
excessive mitochondrial ROS in ASM cells of patients with
COPD, and this might contribute to their proinflammatory and
enhanced proliferative properties. In addition, this acquired
mitochondrial dysfunction might be important in the develop-
ment of comorbidities and in responses to infections that are
common in patients with COPD. Mitochondria-directed
antioxidants represent a more logical approach to the treatment
of COPD by reversing inflammatory and remodeling processes in
patients with COPD that are not treatable at present.
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Key messages
d Ozone exposure in mice induces inflammation, airway hy-
persensitivity, and mitochondrial dysfunction, which are
reversed by treatment with the mitochondria-specific
antioxidant MitoQ.
d ASM cells isolated from patients with COPD have
impaired mitochondrial function, which is not further
induced by oxidative stress.
d Oxidative stress induces mitochondrial dysfunction in
ASM cells from healthy subjects compared with ASM
from patients with COPD, which can be prevented by
mitochondria-directed antioxidant treatment.
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